MONTREAL--SignalGene announced that it has formed a functional genomics collaboration with the National Research Council of Canada’s Institute for Biological Sciences to study neurodegenerative diseases. The collaboration’s objective is to identify novel targets to develop new therapeutic drugs to treat disorders such as Alzheimer’s and Parkinson’s diseases.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.